

Financial Tear Sheet

Corporate Profile

Amgen, the world's largest biotechnology company, uses science and innovation in an effort to dramatically improve people's lives. Amgen aspires to be the world's best human therapeutics company.

Our researchers harness the powerful tools of cellular and molecular biology and medicinal chemistry to discover, develop and commercialize naturally occurring proteins, antibodies and small molecules, with the goal of extending the reach of science to unleash the body's own powerful therapeutic responses. Amgen's research and product development programs aim to help patients in four critical areas: nephrology, hematology and oncology, bone and inflammation, neurology and endocrinology.

Stock Performance

AMGN (COMMON STOCK)	
Exchange	NASDAQ (US Dollar)
Price	\$195.59
Change (%)	▼ 1.8 (0.91%)
Volume	2,015,627
52 Week Low	\$163.31
Market Cap	\$126,599,943,585
Rolling EPS	3.71
PE Ratio	52.7197
Shares Outstanding	647,272,067



Data as of 10/15/18 4:00 p.m. ET

Recent Headlines

10/01/18

FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m² In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma

09/24/18

BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia

09/20/18


Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA

Upcoming Events

DATE	TITLE
10/30/18 5:00 p.m. ET	Q3 2018 Amgen Earnings Conference Call

Analyst Estimates / Ratings

Mean Recommendation: **2.3**



Unable to fulfill request.

SEC Filings

FILING DATE	FORM
09/11/18	3
08/14/18	4
08/06/18	4
08/02/18	3

Financial Reports

Q4 2017 Financial Results

Presentations

09/14/18 Amgen Inc. at the BofAML Global Health Conference 2018 Presentation

Data provided by Nasdaq. Minimum 15 minutes delayed.